openPR Logo
Press release

Antimalarial Drugs Market 2020 Size, Share, Company Profiles and Key Regions 2026 Available at Market Reports World

02-10-2021 03:23 PM CET | Health & Medicine

Press release from: Allied Market Research

Anti-Malarial Drug Market

Anti-Malarial Drug Market

Malaria is a deadly infectious disease, which is transmitted through the bite of female Anopheles mosquito. The infection spreads to liver cells where the parasites multiply at a fast rate to invade red blood cells. These parasites further grow and mature in red blood cells to form merozoites, which are released upon the rupture of red blood cells to invade other blood cells. This leads to fever, tiredness, vomiting, headaches, impaired consciousness, multiple convulsions, and abnormal bleeding. Hence, the drugs which are employed in the treatment of malarial infection are called as antimalarial drugs. There are different types of antimalarial drugs such as quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others available in the market.

The global antimalarial drugs market was valued at $711,360 thousand in 2018, and is expected to reach $1,019,396 thousand by 2026, registering a CAGR of 4.6% from 2019 to 2026.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/2760

The major factor that drives the growth of the antimalarial drugs market include rise in prevalence of malaria in developing countries. Furthermore, rise in awareness initiatives by governments and surge in research for new antimalarial drugs are some of the factors that boost the growth of the market. However, lack of awareness about healthcare in developing countries is a major factor that restricts the growth of the antimalarial drugs market in the region. Conversely, growth opportunities exhibited by emerging economies are expected to offer lucrative opportunities during the forecast period.

The antimalarial drugs market size is studied on the basis of drug class, distribution channel, and region to provide a detailed assessment of the market. On the basis of drug class, it is segmented into quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others. By distribution channel, it is bifurcated into hospital pharmacy, retail pharmacy, and e-commerce & other distribution channel. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, and rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

According to drug class, the others segment occupied the major share of the antimalarial drugs market. Furthermore, the segment is also expected to exhibit the fastest growth rate during the forecast period, owing to the factor that malaria parasites have successfully developed resistance against most of the drugs already available in the market.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2760

By distribution channel, the hospital pharmacy segment acquired the major share due to rise in number of hospitals worldwide. Furthermore, antimalarial drugs are prescription-based medications, which are mostly prescribed by the specialized healthcare professionals available in hospitals; thereby, propelling the growth of this segment. Conversely, the e-commerce segment is expected to exhibit the fastest growth rate during the forecast period, owing to surge in the use of internet across the globe.

By region, North America accounted for the major antimalarial drugs market share in 2018 and is expected to continue this trend, owing to easy availability of antimalarial drugs. Moreover, surge in incidence of malaria is another major reason that contributes to the growth of this market. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period due to increase in awareness regarding the use of antimalarial drugs. Furthermore, constantly evolving life science industry drives the growth of the market in developing economies such as India, China, and Malaysia. As the constant development leads to surge in awareness related to the use of antimalarial drugs. In addition, it also leads to rise in aesthetic consciousness among people; which further fuels the growth of the market.

The Major Key Players Are:

Alvizia Healthcare Pvt. Ltd., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Ipca Laboratories Ltd., Merck & Co., Inc, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories), and Zydus Cadila.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antimalarial Drugs Market 2020 Size, Share, Company Profiles and Key Regions 2026 Available at Market Reports World here

News-ID: 2240099 • Views:

More Releases from Allied Market Research

Neobanking Market Size to Generate $3.3 Trillion by 2032 at 9.0% CAGR | Increase …
Allied Market Research published a report, titled, "Neobanking Market by Account Type (Business Account and Savings Account), Service Type (Mobile Banking, Payments & Money Transfer, Checking/Saving Accounts, Loans, and Others), and Application (Enterprise, Personal): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the global Neobanking Market was valued at $68.95 billion in 2022 and is estimated to reach $3,251.95 billion by 2032, exhibiting a CAGR of 47.3%
Singapore Remittance Market Outlook 2023-2032: Size, Share & Trends
Allied Market Research has published a report titled, "Singapore Remittance Market by Type (Inward Remittance and Outward Remittance), Channel (Banks, Money Transfer Operators, and Others), Application (Consumption, Savings, and Investment), Mode (B2B, B2C, C2B, and C2C), and End User (Migrant Labor Workforce, Low-Income Households, Small Businesses, and Others): Opportunity Analysis and Industry Forecast, 2023-2032." According to the report, the Singapore remittance market was valued at $528.04 million in 2022 and is
Premium Finance Market to Hit $139.7 Billion by 2032, Driven by Growing Insuranc …
According to a new report published by Allied Market Research, titled, "Premium Finance Market by Type (Life Insurance and Non-life Insurance), by Interest Rate (Fixed Interest Rate and Floating Interest Rate), and by Provider (Banks, NBFCs, and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032," the premium finance market was valued at $47.8 billion in 2022 and is projected to reach $139.7 billion by 2032, registering a CAGR of 11.5%
Insurance Claims Services Market to Hit $638.3 Billion by 2032, Growing at 12.8% …
According to a new report published by Allied Market Research, titled, "Insurance Claims Services Market," the market was valued at $193.8 billion in 2022 and is projected to reach $638.3 billion by 2032, growing at a CAGR of 12.8% from 2023 to 2032. Get a Sample Copy of this Report : https://www.alliedmarketresearch.com/request-sample/A09995 The increasing integration of advanced technologies such as artificial intelligence (AI), data analytics, and automation has revolutionized the claims process

All 5 Releases


More Releases for Drug

Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights: * Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029 * Global and Regional Antibody Drug Conjugate Market Insight * Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023 * Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight * Insight On Antibody Drug Conjugates In Clinical Trials: > 550
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase